Interim report January–June 2026

This reads more like a margin-repair phase than a clean demand inflection. When top-line momentum is still negative, the market will discount reported profitability unless management can show that the cost program is creating durable operating leverage rather than just offsetting volume weakness. The 97% cash conversion matters, but it also raises the question of whether working-capital release is flattered this quarter and therefore less repeatable over the next 1-2 quarters.

The main second-order winner is the company’s stronger North America franchise and, by extension, peers with higher US mix and better pricing power. The losers are Europe-heavy competitors and suppliers exposed to discretionary industrial spend, where price competition can intensify if this firm keeps defending EBITDA with cost cuts. If the European improvement proves real, it could force a broader read-through on regional margin recovery; if not, the market will conclude the turnaround story is being financed by temporary working-capital discipline, not end-demand strength.

Near term, the stock should trade on whether the next update confirms that margin gains survive another weak revenue print. A reversal would likely come from either sustained organic growth in North America or evidence that Europe is inflecting broadly across the peer set; absent that, this can still de-rate on low-growth skepticism. The contrarian view is that consensus may be underestimating how quickly a 97% cash-conversion profile can support balance-sheet optionality and valuation, but that only matters if revenue stabilizes first.